CA2447873A1 - Methode et systeme pour ameliorer les systemes vasculaires par feed-back biologique et reseautage - Google Patents
Methode et systeme pour ameliorer les systemes vasculaires par feed-back biologique et reseautage Download PDFInfo
- Publication number
- CA2447873A1 CA2447873A1 CA002447873A CA2447873A CA2447873A1 CA 2447873 A1 CA2447873 A1 CA 2447873A1 CA 002447873 A CA002447873 A CA 002447873A CA 2447873 A CA2447873 A CA 2447873A CA 2447873 A1 CA2447873 A1 CA 2447873A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- data
- vascular
- monitoring device
- recited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 title claims abstract description 89
- 230000006855 networking Effects 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 113
- 238000012806 monitoring device Methods 0.000 claims abstract description 72
- 208000019553 vascular disease Diseases 0.000 claims abstract description 59
- 230000006438 vascular health Effects 0.000 claims abstract description 53
- 238000011221 initial treatment Methods 0.000 claims abstract description 9
- 230000002093 peripheral effect Effects 0.000 claims abstract description 7
- 230000003993 interaction Effects 0.000 claims description 82
- 230000036772 blood pressure Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 235000016709 nutrition Nutrition 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 5
- 230000004218 vascular function Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 claims 2
- 238000011156 evaluation Methods 0.000 description 32
- 238000004891 communication Methods 0.000 description 31
- 230000006870 function Effects 0.000 description 31
- 238000010586 diagram Methods 0.000 description 30
- 238000013459 approach Methods 0.000 description 24
- 230000008569 process Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 230000036541 health Effects 0.000 description 18
- 230000004044 response Effects 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 210000001367 artery Anatomy 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 238000002483 medication Methods 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 230000000386 athletic effect Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 230000007505 plaque formation Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000009877 rendering Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010014476 Elevated cholesterol Diseases 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000001497 healthy food Nutrition 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000012696 congenital leptin deficiency Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005584 early death Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000009532 heart rate measurement Methods 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013474 audit trail Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000002554 cardiac rehabilitation Methods 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/022—Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/486—Biofeedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/56—Details of data transmission or power supply
- A61B8/565—Details of data transmission or power supply involving data transmission via a network
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/06—Measuring blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/56—Details of data transmission or power supply
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Primary Health Care (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
L'invention concerne des méthodes pour traiter des affections vasculaires et pour générer des données représentant des plans de traitement. Un serveur de centre informatique, en communication avec un réseau de données, reçoit de la part d'une personne soignante un premier ensemble de données cliniques représentant la santé vasculaire d'un patient. Un ou plusieurs algorithmes d'analyse d'affections vasculaires sont appliqués au premier ensemble de données d'état vasculaire, pour se traduire par la création et la conservation d'un plan de traitement initial pour le patient. Un deuxième ensemble de données d'état vasculaire est envoyé par un dispositif de surveillance associé au patient, ce deuxième ensemble de données comprenant des données de surveillance Doppler obtenues sur le système vasculaire périphérique du patient. Les algorithmes d'analyse sont appliqués pour établir un ou plusieurs plans de traitement supplémentaires pour le patient, un des plans au moins comprenant une interaction de feed-back biologique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29576801P | 2001-06-05 | 2001-06-05 | |
| US60/295,768 | 2001-06-05 | ||
| PCT/US2002/018073 WO2002099600A2 (fr) | 2001-06-05 | 2002-06-05 | Methode et systeme pour ameliorer les systemes vasculaires par feed-back biologique et reseautage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2447873A1 true CA2447873A1 (fr) | 2002-12-12 |
Family
ID=23139155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002447873A Abandoned CA2447873A1 (fr) | 2001-06-05 | 2002-06-05 | Methode et systeme pour ameliorer les systemes vasculaires par feed-back biologique et reseautage |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2002310346A1 (fr) |
| CA (1) | CA2447873A1 (fr) |
| GB (1) | GB2393547A (fr) |
| WO (1) | WO2002099600A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417248A (zh) * | 2013-08-09 | 2013-12-04 | 深圳市理邦精密仪器股份有限公司 | 一种多普勒仪系统及其通信方法 |
| CN107440695A (zh) * | 2016-05-31 | 2017-12-08 | 永龄生技股份有限公司 | 生理信号感测装置 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8020564B2 (en) * | 2003-12-01 | 2011-09-20 | Carefusion 303, Inc. | System and method for analyzing medical treatment data |
| US8554480B2 (en) * | 2004-03-25 | 2013-10-08 | Siemens Medical Solutions Usa, Inc. | Treatment data processing and planning system |
| US8313433B2 (en) | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
| US8775207B2 (en) | 2005-02-02 | 2014-07-08 | Siemens Medical Solutions Usa, Inc. | Integrated treatment planning and scheduling system |
| RU2309668C1 (ru) | 2006-02-20 | 2007-11-10 | Александр Сергеевич Парфенов | Способ неинвазивного определения функции эндотелия и устройство для его осуществления |
| US9330237B2 (en) | 2008-12-24 | 2016-05-03 | Medtronic Minimed, Inc. | Pattern recognition and filtering in a therapy management system |
| US8057400B2 (en) | 2009-05-12 | 2011-11-15 | Angiologix, Inc. | System and method of measuring changes in arterial volume of a limb segment |
| TWI430201B (zh) * | 2011-01-31 | 2014-03-11 | Yuekang Healthcare Man Consultants Inc | 人體狀況之整合管理系統及其管理方法 |
| US10540448B2 (en) | 2013-07-15 | 2020-01-21 | Cerner Innovation, Inc. | Gap in care determination using a generic repository for healthcare |
| USD832874S1 (en) | 2015-02-19 | 2018-11-06 | Cerner Innovation, Inc. | Display screen with graphical user interface |
| CN109671482A (zh) * | 2017-10-13 | 2019-04-23 | 程景丽 | 一种健康管理方法及系统 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319201B1 (en) * | 1997-10-15 | 2001-11-20 | Peter J. Wilk | Imaging device and associated method |
| JP4702968B2 (ja) * | 1999-08-25 | 2011-06-15 | 株式会社東芝 | 超音波診断装置 |
-
2002
- 2002-06-05 CA CA002447873A patent/CA2447873A1/fr not_active Abandoned
- 2002-06-05 WO PCT/US2002/018073 patent/WO2002099600A2/fr not_active Application Discontinuation
- 2002-06-05 AU AU2002310346A patent/AU2002310346A1/en not_active Abandoned
- 2002-06-05 GB GB0400084A patent/GB2393547A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417248A (zh) * | 2013-08-09 | 2013-12-04 | 深圳市理邦精密仪器股份有限公司 | 一种多普勒仪系统及其通信方法 |
| CN103417248B (zh) * | 2013-08-09 | 2015-04-22 | 深圳市理邦精密仪器股份有限公司 | 一种多普勒仪系统及其通信方法 |
| CN107440695A (zh) * | 2016-05-31 | 2017-12-08 | 永龄生技股份有限公司 | 生理信号感测装置 |
| CN107440695B (zh) * | 2016-05-31 | 2020-10-16 | 佳纶生技股份有限公司 | 生理信号感测装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0400084D0 (en) | 2004-02-04 |
| WO2002099600A2 (fr) | 2002-12-12 |
| WO2002099600A3 (fr) | 2003-05-01 |
| GB2393547A (en) | 2004-03-31 |
| AU2002310346A1 (en) | 2002-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7074183B2 (en) | Method and system for improving vascular systems in humans using biofeedback and network data communication | |
| US7364544B2 (en) | System for improving vascular systems in humans using biofeedback and network data communication | |
| US8005691B2 (en) | System and method for communicating physiological data over a wide area network | |
| WO2017166074A1 (fr) | Procédé et dispositif de traitement de données | |
| US9101334B2 (en) | Method and system for real time visualization of individual health condition on a mobile device | |
| JP2018122110A (ja) | 患者に施される身体のリハビリテーションを増強するための非侵襲性動作追跡システム | |
| CN107480462A (zh) | 智慧临床交互系统 | |
| CA2447873A1 (fr) | Methode et systeme pour ameliorer les systemes vasculaires par feed-back biologique et reseautage | |
| Anderson | The advanced practice nurse cardiovascular clinician | |
| Hanak et al. | A mobile approach to ambient assisted living | |
| Korzh | Digital Technologies in healthcare: promises and challenges | |
| Elshourbagy et al. | Feasibility of virtual low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson’s disease | |
| US20230255498A1 (en) | Monitoring users with a mobile device while the users engage in activities | |
| US20240029888A1 (en) | Generating and traversing data structures for automated classification | |
| US20230293019A1 (en) | Automatically generating protocols or reports based on sensor data from a mobile device | |
| Abdullah et al. | Patient home monitoring system using wearable device | |
| Harris | Effects of a home-based exercise program on perception of illness and adaptation in heart failure patients | |
| Gay et al. | Feasibility trial of a novel mobile cardiac rehabilitation application | |
| Johnson et al. | Telehealth | |
| CARE | Outcomes Evaluation in Cardiac Rehabilitation/Secondary Prevention Programs | |
| Austin et al. | Evaluating tilt table testing in syncope 1: the procedure. | |
| Blanc et al. | EFFECTS OF HOLISTIC CARDIAC REHABILITATION ON ANXIETY AND DEPRESSION: GENDER DIFFERENCE: 11: 30 AM | |
| Brunswick et al. | Alternate Cardiac Rehabilitation Models Using Case Management and Chronic Disease Management Frameworks | |
| Arena et al. | A HYPERTENSIVE DIASTOLIC BLOOD PRESSURE DURING EXERCISE IS ASSOCIATED WITH DYSLIPIDEMIA IN APPARENTLY HEALTHY SUBJECTS: Exercise Testing; Primary Prevention/Epidemiology: Poster# 14 | |
| Recalde et al. | CLINICAL APPLICATION OF THE TALK TEST PROVIDES OUTCOMES FOR THE CARDIAC REHABILITATION SETTING: Cardiac Rehabilitation: Poster# 66 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |